ADC Therapeutics SA (NYSE:ADCT) Stock Has Average Target Price of $5.00

Key Points

• Analysts have a consensus “Hold” rating on ADC Therapeutics, with three buys, two holds and one sell among six firms. The average 12-month price target is $5.00, well above the stock’s reported $1.26 price.
• ADC Therapeutics reported quarterly revenue of $19.25 million and an adjusted loss of $0.11 per share, beating analyst estimates of $18.89 million and a $0.22 loss, respectively.
• The stock has traded between $0.78 and $4.98 over the past year, while institutional investors own 41.1% of the company. ADC’s lead product, Zynlonta, is approved in the U.S. for certain relapsed or refractory large B-cell lymphoma cases.

Shares of ADC Therapeutics SA (NYSE:ADCT - Get Free Report) have been given an average recommendation of "Hold" by the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $5.00.

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ADC Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised ADC Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Finally, Guggenheim lowered their price objective on ADC Therapeutics to $5.00 and set a "buy" rating for the company in a research report on Monday, August 17th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in ADC Therapeutics in the first quarter valued at $38,000. Quantinno Capital Management LP raised its position in shares of ADC Therapeutics by 36.0% in the 1st quarter. Quantinno Capital Management LP now owns 14,719 shares of the company's stock worth $55,000 after acquiring an additional 3,894 shares in the last quarter. AXQ Capital LP bought a new position in shares of ADC Therapeutics in the 2nd quarter worth about $29,000. Sei Investments Co. lifted its stake in shares of ADC Therapeutics by 45.6% in the 1st quarter. Sei Investments Co. now owns 33,461 shares of the company's stock valued at $125,000 after purchasing an additional 10,472 shares during the period. Finally, Walleye Capital LLC acquired a new position in shares of ADC Therapeutics in the 1st quarter valued at about $290,000. Institutional investors own 41.10% of the company's stock.

ADC Therapeutics Stock Performance

Shares of NYSE ADCT opened at $1.26 on Wednesday. ADC Therapeutics has a 52-week low of $0.78 and a 52-week high of $4.98. The firm has a 50 day moving average price of $1.14 and a two-hundred day moving average price of $2.10. The stock has a market cap of $161.50 million, a P/E ratio of -1.92 and a beta of 1.86.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.11. The business had revenue of $19.25 million for the quarter, compared to the consensus estimate of $18.89 million. Analysts predict that ADC Therapeutics will post -0.8 earnings per share for the current fiscal year.

About ADC Therapeutics

ADC Therapeutics SA NYSE: ADCT is a commercial-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC technology is designed to use antibodies to selectively deliver potent cytotoxic agents to cancer cells, with the goal of limiting exposure to healthy tissue.

The company's lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed at the CD19 antigen. Zynlonta is approved in the United States for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.